{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:16:29Z","timestamp":1782724589799,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","award":["Kyoto University Research Development Program"],"award-info":[{"award-number":["Kyoto University Research Development Program"]}],"id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00280-017-3249-1","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T15:06:37Z","timestamp":1487171197000},"page":"629-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-1990","authenticated-orcid":false,"given":"Yoshitaka","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Horimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin\u2019ichi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"3249_CR1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","volume":"6","author":"HM Pinedo","year":"1988","unstructured":"Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653\u20131664","journal-title":"J Clin Oncol"},{"key":"3249_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/archneur.1970.00480260061008","volume":"23","author":"H Koenig","year":"1970","unstructured":"Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155\u2013160. doi: 10.1001\/archneur.1970.00480260061008","journal-title":"Arch Neurol"},{"key":"3249_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/bjc.1997.79","volume":"75","author":"KH Yeh","year":"1997","unstructured":"Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464\u2013465","journal-title":"Br J Cancer"},{"key":"3249_CR4","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.11405\/nisshoshi.106.1744","volume":"106","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Kobashikawa K, Tamura J et al (2009) A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer. Nihon Shokakibyo Gakkai Zasshi 106:1744\u20131750. doi: 10.11405\/nisshoshi.106.1744","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"3249_CR5","first-page":"483","volume":"40","author":"N Misumi","year":"2013","unstructured":"Misumi N, Goto T, Miyoshi T et al (2013) Risk factors for hyperammonemia during mFOLFOX6 treatment. Gan To Kagaku Ryoho 40:483\u2013487","journal-title":"Gan To Kagaku Ryoho"},{"key":"3249_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.11405\/nisshoshi.112.287","volume":"112","author":"T Iida","year":"2015","unstructured":"Iida T, Wagatsuma K, Tani M et al (2015) Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis. Nihon Shokakibyo Gakkai Zasshi 112:287\u2013296. doi: 10.11405\/nisshoshi.112.287","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"3249_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00280-011-1633-9","volume":"68","author":"T Horimatsu","year":"2011","unstructured":"Horimatsu T, Miyamoto S, Morita S et al (2011) Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68:263\u2013266. doi: 10.1007\/s00280-011-1633-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"3249_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","volume":"26","author":"E Gamelin","year":"2008","unstructured":"Gamelin E, Delva R, Jacob J et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099\u20132105. doi: 10.1200\/JCO.2007.13.3934","journal-title":"J Clin Oncol"},{"key":"3249_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.anl.2007.04.012","volume":"35","author":"S Kikuta","year":"2008","unstructured":"Kikuta S, Asakage T, Nakao K et al (2008) The aggravating factors of hyperammonemia related to 5-fluorouracil infusion\u2013a report of two cases. Auris Nasus Larynx 35:295\u2013299. doi: 10.1016\/j.anl.2007.04.012","journal-title":"Auris Nasus Larynx"},{"key":"3249_CR10","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie GD, Sommadossi JP, Cross DS et al (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203\u20132206","journal-title":"Cancer Res"},{"key":"3249_CR11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00686286","volume":"35","author":"L Thiberville","year":"1994","unstructured":"Thiberville L, Compagnon P, Moore N et al (1994) Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 35:64\u201370","journal-title":"Cancer Chemother Pharmacol"},{"key":"3249_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.phrs.2004.01.006","volume":"50","author":"F Casale","year":"2004","unstructured":"Casale F, Canaparo R, Serpe L et al (2004) Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50:173\u2013179. doi: 10.1016\/j.phrs.2004.01.006","journal-title":"Pharmacol Res"},{"key":"3249_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","volume":"43","author":"SM Lichtman","year":"2007","unstructured":"Lichtman SM, Wildiers H, Launay-Vacher V et al (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14\u201334. doi: 10.1016\/j.ejca.2006.11.004","journal-title":"Eur J Cancer"},{"key":"3249_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","volume":"21","author":"N Janus","year":"2010","unstructured":"Janus N, Thariat J, Boulanger H et al (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21:1395\u20131403. doi: 10.1093\/annonc\/mdp598","journal-title":"Ann Oncol"},{"key":"3249_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00228-002-0534-6","volume":"58","author":"G Bocci","year":"2002","unstructured":"Bocci G, Danesi R, Allegrini G et al (2002) Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol 58:593\u2013595. doi: 10.1007\/s00228-002-0534-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3249_CR16","first-page":"4705","volume":"6","author":"AB Kuilenburg van","year":"2000","unstructured":"van Kuilenburg AB, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705\u20134712","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3249-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:38:27Z","timestamp":1498372707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3249"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3249-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]}}}